scholarly journals Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy

Medicine ◽  
2015 ◽  
Vol 94 (42) ◽  
pp. e1861 ◽  
Author(s):  
Matteo Ferro ◽  
Ottavio De Cobelli ◽  
Carlo Buonerba ◽  
Giuseppe Di Lorenzo ◽  
Marco Capece ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Radical Cystectomy ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Risk Of Recurrence ◽  
Modified Glasgow Prognostic Score

scholarly journals Modified Glasgow prognostic score can predict survival of muscle invasive bladder cancer patients after radiotherapy

2020 ◽  
Vol 61 (4) ◽  
pp. 616-621
Author(s):  
Koyo Kikuchi ◽  
Ryuji Nakamura ◽  
Takafumi Segawa ◽  
Hirobumi Oikawa ◽  
Hisanori Ariga
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Cox Regression Analysis ◽  
Modified Glasgow Prognostic Score ◽  
Kaplan Meier ◽  
Muscle Invasive

Abstract In patients with various cancers, modified Glasgow prognostic score (mGPS) before treatment has predicted prognoses after antitumor therapy. This study aimed to assess whether pretreatment mGPS also has predictive value in patients with muscle-invasive bladder cancer (MIBC) after radiotherapy. A retrospective review accumulated 98 consecutive MIBC patients treated with definitive 3D-conformal radiotherapy from January 2011 to December 2016 in a single center. It included cT2-4bN0-3M0 patients with a median age of 79 years (range: 49 to 95 years). Radiotherapy was delivered at 60–66 Gy for bladder cancer. Patients were categorized in terms of their pretreatment serum albumin and C-reactive protein (CRP) values as mGPS_0, mGPS_1, and mGPS_2. Among them, cumulative overall survival (OS) rates were compared by Kaplan–Meier plots with log-rank tests. The number of patients with mGPS_0, mGPS_1, and mGPS_2 were 40, 40, and 18, respectively. The median follow-up time for all patients was 19 months (range: 2–73 months). The 2-year OS rate for all patients was 75.7%. The 2-year OS rates for mGPS_0, mGPS_1, and mGPS_2 were 85.1%, 71.3%, and 60.9%, respectively. Kaplan–Meier curves revealed a significantly higher cumulative OS rate for mGPS_0 compared with mGPS_1 and mGPS_2 (P = 0.003). Using multivariate Cox regression analysis, mGPS_0 and good performance status were associated with favorable OS rates, of which mGPS_0 was more significant (Hazard ratio 2.74, 95% CI 1.30–5.57, P = 0.008). Modified Glasgow prognostic score may be a novel biomarker that can predict survival in patients with MIBC after radiotherapy.

scholarly journals Assessment of Cachexia in Head and Neck Cancer Patients Based on a Modified Glasgow Prognostic Score

2016 ◽  
Vol 119 (2) ◽  
pp. 125-128
Author(s):  
Takashi Matsuzuka ◽  
Masahiro Suzuki ◽  
Satoshi Saijoh ◽  
Masakazu Ikeda ◽  
Mitsumasa Imaizumi ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Modified Glasgow Prognostic Score

Modified Glasgow Prognostic Score (mGPS) for Prognostication of Adult Oncology Patients With Palliative Intent in a Regional Victorian Hospital, Australia

2020 ◽  
pp. 104990912095838
Author(s):  
Nuttaradee Lojanapiwat ◽  
Md Rafiqul Islam ◽  
Martin Ridout ◽  
Sivakumar Subramaniam
Keyword(s):  
Cancer Patients ◽  
Median Survival ◽  
Cox Regression ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
P Value ◽  
C Reactive Protein ◽  
Cox Regression Analysis ◽  
Reactive Protein ◽  
Modified Glasgow Prognostic Score

Background: Accurate prognostication is essential in caring for palliative patients. Various prognostication tools have been validated in many settings in the past few years. Biomarkers of inflammation (albumin and C-reactive protein) are combined to calculate the modified Glasgow prognostic score (mGPS), which has been found to be a simple prognostic tool in this population. Objective: This retrospective cohort study was to evaluate mGPS as a prognostication tool for cancer patients admitted to an acute hospital in regional Australia. Methods: Adult cancer patients admitted to an acute Australian regional hospital during 2017 who had albumin and C-reactive protein (CRP) tested were included. The mGPS was calculated based on their admission values and discharge values. Based on their score (0-2), groups were compared using univariate and multivariate Cox regression analysis for prognostication. Kaplan-Meier survival plots and median survival time from admission and discharge were constructed. Results: A total of 170 patient records were reviewed of which 95 had admission and discharge mGPS scores available for analysis. Of those, 86 had died at the time of data analysis. The median survival for admission mGPS 0, 1, 2 was 168,156 and 74 days. For discharge mGPS 0, 1, 2 medians were 168,119 and 70 days. On multi variate analysis admission mGPS 2 showed Hazard ratio of 2.29 (95% CI 1.16-4.56, p -0.02) and discharge mGPS 2 of 2.07 (95% CI 0.95-4.50, p value 0.07). Conclusions: In this study, mGPS was able to differentiate cancer patients into various prognostic groups. Further studies in regional acute hospitals could validate this prospectively with a multi-center larger sample size.

Systemic inflammatory response to predict clinical outcome in patients with resected pancreatic cancer treated with adjuvant gemcitabine monotherapy.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 223-223
Author(s):  
Soichiro Morinaga ◽  
Takuo Watanabe ◽  
Masakatsu Numata ◽  
Yo Mikayama ◽  
Hiroshi Tamagawa ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Outcome ◽  
Inflammatory Response ◽  
Cancer Patients ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Systemic Inflammatory Response ◽  
Rank Test ◽  
Poor Clinical Outcome ◽  
Modified Glasgow Prognostic Score

223 Background: Systemic inflammatory response (SIR) has been shown to associate with poor outcome in either inoperable or operable pancreatic cancer. However, whether the presence of a SIR predicts poor clinical outcome of pancreatic cancer patients in adjuvant setting is unclear. The aim of present study was to determine the relationship between SIR, as evaluated by Modified Glasgow prognostic score (mGPS), and outcome of pancreatic cancer patients treated with adjuvant chemotherapy. Methods: A total of 42 resected pancreatic cancer patients were analyzed for mGPS before adjuvant gemcitabine chemotherapy. The mGPS was constructed as follows: patients with both an elevated C-reactive protein (> 0.3mg/dl) and hypoalbuminaemia (< 3.5mg/dl) were allocated a score of 2. Patients with one or none of these abnormalities were allocated a score of 1or 0, respectively. Results: There were 25 patients assigned to score 0, 12 patients to score 1, and 5 patients to score 2. The median OS in patients with score 0, score 1, and score 2 were 23.9 months, 10.3 months, and 9.9 months, respectively. The DFS in patients with score 0, score 1, and score 2 were 11.0 months, 5.9 months, and 3.6 months, respectively. The OS and DFS after surgery of the patients with SIR (score 1 and 2) were significantly poorer than that of the patients with score 0 (P=0.0278 for OS, P=0.0011 for DFS by log-rank test). Conclusions: The presence of SIR, as evaluated by Modified Glasgow prognostic score (mGPS), predicts poor clinical outcome in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.

scholarly journals PO-0831: Modified Glasgow prognostic score can predict survival in elderly patients with bladder cancer

2018 ◽  
Vol 127 ◽  
pp. S434
Author(s):  
K. Kikuchi ◽  
R. Nakamura ◽  
T. Segawa ◽  
H. Kakuhara ◽  
H. Oikawa ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Elderly Patients ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Modified Glasgow Prognostic Score
Sign in / Sign up

Export Citation Format

Share Document